CO4410330A1 - Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida - Google Patents

Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida

Info

Publication number
CO4410330A1
CO4410330A1 CO95035006A CO95035006A CO4410330A1 CO 4410330 A1 CO4410330 A1 CO 4410330A1 CO 95035006 A CO95035006 A CO 95035006A CO 95035006 A CO95035006 A CO 95035006A CO 4410330 A1 CO4410330 A1 CO 4410330A1
Authority
CO
Colombia
Prior art keywords
benzmidazole
pharmacologically active
new derivatives
additional salts
salts
Prior art date
Application number
CO95035006A
Other languages
English (en)
Inventor
William S Faraci
Neill Brian T O
Mark A Sanner
Stevin H Zorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4410330A1 publication Critical patent/CO4410330A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVOS DERIVADOS DE BENCIMIDAZOL FARMACEUTICAMENTE ACTIVOS DE FORMULA (I) ESTOS COMPUESTOS MUESTRAN ACTIVIDAD DIPAMINERGICA CENTRAL Y SON UTILES EN EL TRATAMIENTO DE TRASTOR- NOS DEL SISTEMA NERVIOSO CENTRAL (SNC). ESTOS AC- TUAN PREFERENTEMENTE SOBRE EL RECEPTOR DE DOPAMINA D4. EN LA FORMULA (I) CADA UNA DE LAS LINEAS PUNTEADAS REPRESENTA UN DOBLE ENLACE OPCIONAL; X ES CARBONO O NITROGENO; R1 ES BENCILO, ARILO SELECCIONADO ENTRE FENILO, INDANILO Y NAFTILO, O HETEROARILO... R2 y R3 SE SELECCIONAN DE FORMA INDEPENDIENTE EN- TRE HIDROGENO, HIDROXI, ALQUILO DE C1-C6, ALCOXI DE C1-C6, CIANO, -CONH2 y -NHC(=O)R9, o R2 y R3 JUNTOS FORMAN UN GRUPO OXO; R4 ES HIDROGENO, AZUFRE, OXIGENO, ALQUILO DE C1- C6, AMINO, -NHR10, -SR10, OR10 o HIDROXI; R5,R6 y R7 SE SELECCIONAN INDEPENDIENTEMENTE ENTRE HIDROGENO, HALO, CIANO, ALQUILO DE C1-C6... R8, R9 y R10 SE SELECCIONAN DE FORMA INDEPENDIENTE ENTRE HIDROGENO Y ALQUILO DE C1-C6; Y R11 ES HIDROGENO, ALQUILO DE C1-C6 o BENCILO, EN EL QUE EL RADICAL FENILO PUEDE ESTAR OPCIONALMENTE SUSTITUIDO... CADA UNO DE R15 y R16 SE SELECCIONA DE FORMA IN- DEPENDIENTE ENTRE HIDROGENO, METILO, CIANO, -(C=O) -NH2 y -CH2-O- ALQUILO DE C1-C6; R17 ES HIDROGENO O, CUANDO X ES NITROGENO, R17 PUEDE FORMAR OPCIONALMENTE, JUNTO CON EL CARBONO AL CUAL ESTA UNIDO, R1 y X, UN ANILLO DE TETRAHI- DROQUINOLINA; CON LA CONDICION DE QUE: (a) R4 NO PUEDE SER OXIGENO O HIDROXI CUANDO TO- DOS LOS R2, R3, R15 y R16 SON HIDROGENO; (b) CUANDO EL ANILLO DE CINCO ESLABONES DE FORMU- LA I CONTIENE UN DOBLE ENLACE, R11 NO ESTA PRESEN- TE; (c) CUANDO R4 ES AZUFRE U OXIGENO, R4 ESTA UNIDO POR UN DOBLE ENLACE CON EL CARBONO AL CUAL ESTA U- NIDO Y DICHO CARBONO ESTA UNIDO POR ENLACE SENCI- LLO A AMBOS ATOMOS DE NITROGENO ADYACENTES; Y (d) CUANDO X ES NITROGENO Y ESTA UNIDO POR UN EN- LACE DOBLE A UN CARBONO ADYACENTE, R1 NO ESTA PRE- SENTE; O UNA DE SUS SALES FARMACEUTICAMENTE ACEP- TABLES. FIGURA 1
CO95035006A 1994-08-05 1995-08-04 Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida CO4410330A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28657694A 1994-08-05 1994-08-05
US29800594A 1994-08-30 1994-08-30

Publications (1)

Publication Number Publication Date
CO4410330A1 true CO4410330A1 (es) 1997-01-09

Family

ID=26963924

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95035006A CO4410330A1 (es) 1994-08-05 1995-08-04 Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida

Country Status (20)

Country Link
EP (1) EP0775118B1 (es)
JP (1) JP3004727B2 (es)
KR (1) KR970704698A (es)
AT (1) ATE242220T1 (es)
AU (1) AU703431B2 (es)
BR (1) BR9503572A (es)
CA (1) CA2196769C (es)
CO (1) CO4410330A1 (es)
DE (1) DE69530988T2 (es)
DK (1) DK0775118T3 (es)
ES (1) ES2201105T3 (es)
FI (1) FI970469A (es)
IL (1) IL114754A0 (es)
MX (1) MX9700959A (es)
NZ (1) NZ284851A (es)
PE (1) PE35796A1 (es)
PT (1) PT775118E (es)
TR (1) TR199500956A2 (es)
TW (1) TW306920B (es)
WO (1) WO1996004250A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205846T1 (de) * 1995-12-21 2001-10-15 Pfizer 2,7-substituierte octahydropyrrolo(1,2- a)pyrazinderivate
EP0953567A3 (en) * 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
AU2152001A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S Phenylpiperazinyl derivatives
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
BR0110450A (pt) * 2000-11-22 2005-02-09 Abbott Lab Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
CA2450315A1 (en) * 2001-06-13 2002-12-19 The Regents Of The University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
WO2003038060A2 (en) 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
JP2005527530A (ja) * 2002-03-12 2005-09-15 ワイス キラル１，４−二置換ピペラジン
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
WO2005080334A1 (ja) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
KR20080097496A (ko) 2004-03-25 2008-11-05 더 리젠츠 오브 더 유니버시티 오브 미시간 고시폴 공결정 및 그의 용도
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP2016500084A (ja) * 2012-11-26 2016-01-07 リアオニン エミー バイオロジカル ファーマシューティカル カンパニー リミテッドＬｉａｏｎｉｎｇ Ｅｍｍｙ Ｂｉｏｌｏｇｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環基ピペリジン又はピペラジン誘導体及びその作製方法並びに薬剤組成物
US9415047B2 (en) * 2012-11-26 2016-08-16 Liaoning Emmy Biological Pharmaceutical Co., Ltd. Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
DK0775118T3 (da) 2003-09-29
DE69530988D1 (de) 2003-07-10
WO1996004250A1 (en) 1996-02-15
FI970469A0 (fi) 1997-02-04
JPH09510706A (ja) 1997-10-28
ATE242220T1 (de) 2003-06-15
DE69530988T2 (de) 2003-12-04
BR9503572A (pt) 1996-04-30
TR199500956A2 (tr) 1996-07-21
PE35796A1 (es) 1996-10-01
KR970704698A (ko) 1997-09-06
AU2351095A (en) 1996-03-04
CA2196769C (en) 2002-10-08
MX9700959A (es) 1997-05-31
EP0775118B1 (en) 2003-06-04
EP0775118A1 (en) 1997-05-28
CA2196769A1 (en) 1996-02-15
JP3004727B2 (ja) 2000-01-31
PT775118E (pt) 2003-10-31
FI970469A (fi) 1997-04-04
ES2201105T3 (es) 2004-03-16
NZ284851A (en) 1998-07-28
AU703431B2 (en) 1999-03-25
IL114754A0 (en) 1995-11-27
TW306920B (es) 1997-06-01

Similar Documents

Publication Publication Date Title
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
SE9504661D0 (sv) New compounds
SE9604786D0 (sv) New compounds
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MY117896A (en) Quinazoline derivatives
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DE69819539D1 (de) Antithrombotische mittel
ATE152708T1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino- tetralinderivate
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
NO20042729L (no) Heksasykliske forbindelser
ATE152450T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepine und ihre pharmazeutisch verträglichen säureadditionssalze
ATE268768T1 (de) Antithrombosemittel
FI933652A (fi) Foerfarande foer framstaellning av 1-osubstituerade 3-aminopyrroler